Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

  1. Ane Ogbe
  2. Matthew Pace
  3. Mustapha Bittaye
  4. Timothy Tipoe
  5. Sandra Adele
  6. Jasmini Alagaratnam
  7. Parvinder K. Aley
  8. M. Azim Ansari
  9. Anna Bara
  10. Samantha Broadhead
  11. Anthony Brown
  12. Helen Brown
  13. Federica Cappuccini
  14. Paola Cinardo
  15. Wanwisa Dejnirattisai
  16. Katie J. Ewer
  17. Henry Fok
  18. Pedro M. Folegatti
  19. Jamie Fowler
  20. Leila Godfrey
  21. Anna L. Goodman
  22. Bethany Jackson
  23. Daniel Jenkin
  24. Mathew Jones
  25. Stephanie Longet
  26. Rebecca A. Makinson
  27. Natalie G. Marchevsky
  28. Moncy Mathew
  29. Andrea Mazzella
  30. Yama F. Mujadidi
  31. Lucia Parolini
  32. Claire Petersen
  33. Emma Plested
  34. Katrina M. Pollock
  35. Thurkka Rajeswaran
  36. Maheshi N. Ramasamy
  37. Sarah Rhead
  38. Hannah Robinson
  39. Nicola Robinson
  40. Helen Sanders
  41. Sonia Serrano
  42. Tom Tipton
  43. Anele Waters
  44. Panagiota Zacharopoulou
  45. Eleanor Barnes
  46. Susanna Dunachie
  47. Philip Goulder
  48. Paul Klenerman
  49. Gavin R. Screaton
  50. Alan Winston
  51. Adrian V.S. Hill
  52. Sarah C. Gilbert
  53. Miles Carroll
  54. Andrew J. Pollard
  55. Sarah Fidler
  56. Julie Fox
  57. Teresa Lambe
  58. John Frater

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1172/jci.insight.157031
  2. ScreenIT

    SciScore for 10.1101/2021.09.28.21264207: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: Written informed consent was obtained from all participants, and the trial was done in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice.
    IRB: Study approval in the UK was done by the Medicines and Healthcare products Regulatory Agency (reference 21584/0424/001-0001) and the South Central Berkshire Research Ethics Committee (reference 20/SC/0145).
    Sex as a biological variablenot detected.
    RandomizationFor some assays and where sample availability allowed, comparison was made with age- and sex-matched participants who were HIV negative, aged 18–55 years, enrolled into the main COV002 phase 2/3 randomised clinical trial, and randomly assigned (5:1) to receive either ChAdOx1 nCoV-19 or MenACWY by intramuscular vaccination.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    After 2-hour incubation and a washing step, detection antibody (MSD SULFO-TAG™ Anti-Human IgG Antibody, 1/200) was added.
    Anti-Human IgG
    suggested: None
    Assays were performed using Multiscreen IP ELISpot plates (Merck Millipore, Watford, UK) coated with 10 μg/mL human anti-IFNγ antibody and developed using SA-ALP antibody conjugate kits (Mabtech, Stockholm, Sweden) and BCIP NBT-plus chromogenic substrate (Moss Inc., Pasadena, MA, USA).
    anti-IFNγ
    suggested: None
    SA-ALP
    suggested: None
    After stimulation cells were stained with the anti-human antibodies contained in supplementary table 6.
    anti-human
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    A MULTI-SPOT® 96-well, 10 spot plate was coated with three SARS CoV-2 antigens (S, RBD, N), SARS-CoV-1 and MERS-CoV spike trimers, as well as spike proteins from seasonal human coronaviruses, HCoV-OC43, HCoV-HKU1, HCoV-229E and HCoV-NL63, and bovine serum albumin.
    HCoV-229E
    suggested: None
    HCoV-NL63
    suggested: RRID:CVCL_RW88)
    The mixtures were then transferred to 96-well, cell culture-treated, flat-bottom microplate containing confluent Vero cell monolayers in duplicate and incubated for further 2 hours, followed by the addition of 1.5% semi-solid carboxymethyl cellulose (CMC) overlay medium to each well to limit virus diffusion.
    Vero
    suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)
    Software and Algorithms
    SentencesResources
    Participants with a history of laboratory-confirmed SARS-CoV-2 infection by anti-N protein IgG immunoassay (Abbott Architect, Abbott Park, IL, USA) at screening were excluded.
    Abbott Architect
    suggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)
    Standardised EUs were determined from a single dilution of each sample against the standard curve which was plotted using the 4-Parameter logistic model (Gen5 v3.09, BioTek).
    Gen5
    suggested: (Gen5, RRID:SCR_017317)
    The percentage of focus reduction was calculated and IC50 (reported as FRNT50) was determined using the probit program from the SPSS package.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)
    The data was analysed using FlowJo version 10 and Prism version 9.
    FlowJo
    suggested: (FlowJo, RRID:SCR_008520)
    Prism
    suggested: (PRISM, RRID:SCR_005375)
    Gating strategies are as shown in supplementary figure 1a and b Phylogenetic analysis: We used protein BLAST to download all human coronavirus S protein sequences from NCBI database.
    BLAST
    suggested: (BLASTX, RRID:SCR_001653)
    NCBI
    suggested: (NCBI, RRID:SCR_006472)
    We used MAFFT to align all chosen human corona viruses, SARS-CoV, MERS-CoV and SARS-CoV-2 S protein sequences.
    MAFFT
    suggested: (MAFFT, RRID:SCR_011811)
    We then calculated the pairwise distances between the sequences and built a neighbour joining tree using MATLAB.
    MATLAB
    suggested: (MATLAB, RRID:SCR_001622)
    We did all analyses using R (version 3.6.1 or later), and Prism 9 (GraphPad Software).
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04400838Active, not recruitingInvestigating a Vaccine Against COVID-19

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.09.28.21264207v1 on medRxiv